tracking the news, one byte at a time
Freak Pulse

Evaluating Alzheimer’s Drugs & Treatments this week: A 2026 Cochrane Review analysis of 17 clinical trials involving over 20,000 participants concludes that anti-amyloid; and This matters for Alzheimer’s Disease and Frontal Temporal…

Anavex Life Sciences presented new long-term data for its investigational oral therapy blarcamesine (Anavex 2-73) at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases.